Western Blot: Complement Component C3a R Antibody [NBP2-15649] - Whole cell extract (30 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with C3a Receptor antibody diluted at 1:1000. The HRP-conjugated ...read more
Genetic Strategies: Immunohistochemistry-Paraffin: Complement Component C3a R Antibody [NBP2-15649] - Tissue staining sections of mouse lung tissue without (left) and with (right) silencing by siRNA. This image ...read more
Immunohistochemistry-Paraffin: Complement Component C3a R Antibody [NBP2-15649] - Human colon carcinoma, using C3a receptor 1 antibody at 1:500 dilution. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, ...read more
WB usage reported in scientific literature (PMID: 26956419). Use in Immunoblotting reported in scientific literature (PMID: 26956419).
54 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Read 1 Review rated 5 using NBP2-15649 in the following applications:
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.